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Summary: 
Fetal fibronectin testing (fFN) has a high negative predictive value for preterm 
delivery, but it has a cost implication. This two stage prospective study 
evaluated the real patient costs and clinical impact of introducing the fFN test 
in women presenting acutely with threatened preterm labour in a tertiary UK 
obstetric hospital. 
Introduction of the fFN test for women with threatened preterm labour reduced 
antenatal admissions and in utero transfers, and reduced steroid treatment 
and tocolysis, even at one year after implementation. The total number of bed 
days for women with threatened preterm labour who did not deliver during 
admission fell from 132 days (mean 8.8 days) to 25 days (mean 3.6 days). 
The mean cost of admission per woman before introduction of the fFN test 
was £1,032 (95% CI £880 to £1184); after it was £339 (95% CI £261 to £417). 
In this small single centre study, the introduction of the test produced a cost 
saving of £693 per woman (95% CI, £464 to £922) which over 12 months 
potentially saves £74,844 (95% CI £50,112 to £99,576). Further studies are 
needed to formally evaluate the cost-effectiveness of the fFN test and its 
impact on clinical decision-making in large populations.  
 
 
Key words: fetal fibronectin, preterm birth, costs 
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Introduction: 
Current antenatal management of women in threatened preterm labour 
relies on timely administration of maternal antenatal steroids, tocolysis to 
delay delivery until fetal lung maturity is reached and in utero transfer to a unit 
with appropriate level neonatal intensive care. Based on clinical judgement 
alone however, fewer than 50% of all women admitted with threatened 
preterm labour actually deliver their baby during that admission (Lockwood et 
al., 1991). Better diagnosis could avoid unnecessary admissions, in utero 
transfer, and treatment with steroids and costly tocolytic drugs.  
Fetal fibronectin (fFN) is a glycoprotein and biochemical marker which 
is detectable in a woman’s cervicovaginal secretions throughout pregnancy, 
with low levels between 22 and 35 weeks of gestation. fFN concentrations 
≥50ng/ml at this time indicate a greater risk of preterm birth in women 
presenting with threatened preterm labour (Peaceman et al., 1997). Using a 
50ng/ml cut-off, the fFN test has a negative predictive value (NPV) of 99.2%, 
and a positive predictive value (PPV) >40% for delivery within 14 days. The 
accuracy in predicting spontaneous preterm birth within 7-10 days of testing 
among women with symptoms of threatened preterm labour before advanced 
cervical dilatation, has been confirmed in large studies (Honest et al., 2002).  
Introduction of the fFN test to the UK and the rest of Europe has been 
slow in comparison to other countries such as Australia (Giles et al., 2000), 
New Zealand (Groom et al., 2006), the United States (Plaut et al., 2003, 
Swamy et al., 2005, Incerti et al., 2007) and Canada (Giles et al., 2000, 
MacDonald et al., 2007). In these countries where the impact of in utero 
transfer is high due to their large distances, implementation of the fFN test 
has been shown to reduce in utero transfers and medical costs. Economic 
analyses of the test have used assumptions to model the data rather than use 
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real-life clinical data sources (Honest et al., 2002). A reduction in costs may 
not be immediately evident (Musaad et al., 2005) and there are concerns that 
increasing clinician reliance on the test with overuse in women presenting with 
abdominal pain may reduce potential cost savings long term. No studies have 
investigated whether the initial cost savings continue long term after 
implementation. In addition the cost savings might depend on whether a unit 
tocolyses with Atosiban (£339 for a course) or cheaper unlicenced 
alternatives such as nifedipine. An alternative to the fFN test is sonographic 
measurement of cervical length (CL), where CL <15 mm indicates a higher 
chance of preterm birth in symptomatic women (Tsoi et al., 2006). In most UK 
hospitals however, accurate sonography is not available after hours or on 
weekends, when many women with threatened preterm labour present to 
hospital.    
In our tertiary obstetric hospital, we hypothesized that introduction of 
the fFN test would safely reduce in-patient admissions, in utero transfer, 
administration of steroids and tocolytics and importantly would result in long 
lasting cost saving.  We quantified the impact of antenatal preterm admissions 
on the hospital before the test in all women presenting acutely with threatened 
preterm labour. After introduction of the fFN test we evaluated the 
performance of the test ten weeks and at one year after implementation in 
women with the same presentation. Finally we calculated the cost savings in 
the departmental budget one year after implementation. 
Materials and Methods: 
University College London Hospital (UCLH) is a tertiary referral centre 
with 5200 deliveries per annum supported by an on-site level 3 neonatal 
intensive care unit. It is the main referral unit for the North Central London 
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Perinatal Network (NCLPN). The practice at UCLH before April 2009 was to 
admit all women presenting acutely to Labour Ward and the day case 
Maternal Fetal Assessment Unit (MFAU) in threatened preterm labour for 
observation, plus a course of maternal steroids and tocolysis (Atosiban). All 
admissions, prescriptions of steroids and tocolytics were based on clinical 
judgement alone as to the likelihood of imminent delivery. Women underwent 
clinical examination, cardiotocography and were observed on the labour ward 
for up to 4 hours. Women thought to be at high risk of spontaneous preterm 
birth were admitted to hospital for at least 24 hours observation.  
 To quantify the cost and impact of preterm antenatal admissions 
on the hospital before introduction of the fFN test, we audited all admissions 
to UCLH between 22 and 34+6 weeks of gestation for 2 months (January- 
February 2009). To ensure complete case ascertainment we audited all 
women who presented acutely in the Labour Ward and in the day case 
Maternal Fetal Assessment Unit (MFAU) at UCLH. Women presenting to 
other parts of the hospital, for example Accident & Emergency, would always 
be referred to LW or MFAU and were not admitted directly to the Antenatal 
Ward. Clinical staff completed an audit proforma when a woman presented 
and was admitted to the Antenatal Ward. To ensure complete case 
assessment the logbooks for Labour Ward and MFAU admissions were 
checked daily and compared with proformas completed prospectively. The 
study team checked the Antenatal and Postnatal Wards daily to ensure 
complete case ascertainment.    
Data on presenting symptoms, vaginal examination findings, diagnosis, all 
investigations performed (including fFN test, ultrasound scans, blood tests 
and microbiology), all treatments (including analgesia, antibiotics, tocolytics), 
length of stay and in utero transfers were collected prospectively and 
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confirmed using the electronic inpatient bed-state. The pregnancy outcome 
was determined from the case notes. Women whose cervix was found to be 
≥3cm dilated on vaginal examination were diagnosed to be in established 
preterm labour. Threatened preterm labour was diagnosed when women 
presented with painful uterine contractions and the cervical dilatation was 
3cm.  
 An automated qualitative fFN test, TLiIQ (Hologic, USA) was introduced 
to the unit in March 2009 supported by a training programme for healthcare 
staff. The unit’s threatened preterm labour guideline was revised to 
incorporate the fFN test into the algorithm, which was then disseminated to 
other hospitals in the NCLPN. The use of and the predictive performance of 
the fFN test was audited in the first 10 weeks of the test and results were 
disseminated to all medical and midwifery staff to support implementation of 
the test.  
Ten months after introduction of the test (January – February 2010) 
and one year after the initial audit of antenatal preterm admissions, we re-
audited all antenatal preterm admissions to UCLH between 22 and 34+6 
weeks. To ensure complete case ascertainment we again audited all women 
who presented acutely in the Labour Ward and in the day case Maternal Fetal 
Assessment Unit (MFAU) at UCLH. Audit proformas, admission logbooks and 
wards were checked daily as described earlier. The fFN machine was 
prospectively checked daily for test usage to ensure that no tests were missed 
out. Over the year following fFN implementation the performance of the test 
was monitored daily. We calculated the impact and costs of care. The 
predictive performance of the fFN test in women with threatened preterm 
labour was monitored over the entire year. Between the two audit time 
periods, mid-trimester cervical length sonography at the time of the anomaly 
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scan was introduced for all women booked at UCLH as a screening test for 
increased risk of spontaneous preterm birth.  All women with an incidental 
finding of a cervical length ≤25mm were referred for a consultant obstetric 
opinion in the UCLH Preterm Birth clinic. 
The costs of all assessments and all treatments that every woman 
underwent before and after implementation of fFN testing were derived. We 
used cost data available from the Primary Care Trust (cost of 24 hour 
admission to the hospital, £420), UCLH pharmacy (£339 per atosiban 
tocolysis, £5 for equipment per infusion, £5 for steroid injection, £10 for 
analgesia; costs included intravenous access, infusion fluids, syringes and 
needles), UCLH pathology services (full blood count, FBC £10; Group and 
Save £20; mid stream urine (MSU) culture £20; high vaginal swab (HVS) for 
culture, £25; costs included syringes and needles, blood bottles and swabs), 
UCLH obstetric ultrasound scan (£70) and the London Ambulance Service (in 
utero transfer cost, £100). The costs are indicated, in Table 3 and were 
measured in 2012 UK£. Discounting of costs was unnecessary, because all 
costs per patient were incurred within a single year. Since all women 
underwent cardiotocography, blood pressure measurement, MSU dipstick and 
review by a midwife and a doctor during their initial presentation to hospital, 
we have not included these costs. To calculate patient costs we split patient 
admissions into two groups dependent on whether the woman received 
tocolysis (defined as a Full admission) or did not receive tocolysis (defined as 
a Minor admission, Table 3). A Minor admission included the hospital 
admission, any laboratory investigations that were performed on the woman, 
a fetal ultrasound scan after admission if clinically indicated, and the use of 
analgesia and steroids as required. Full admission included items provided in 
Minor admission and the use of tocolysis and in utero transfer as required. 
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After introduction of fFN, a Minor or Full admission was as described above, 
but also included the cost of the fFN test when performed. In addition, we 
calculated the cost for women who only had the fFN test after its introduction 
and who were not admitted (fFN only, Table 3); this cost also included the 
cost of tests or treatments that the women underwent as part of their care 
during their hospital consultation, such as for example FBC, MSU, HVS and 
analgesia. For each cost component, for example a bed day, test, scan or 
prescription, the total number incurred before or after implementation of the 
fFN test was calculated from the individual patient audit data results to derive 
the resource use data. Then the unit costs were multiplied by the resource 
use data for each cost component and averaged by the number of women in 
each cohort, either before or after implementation of the fFN test.  The mean 
cost component per patient was then summed to calculate a final mean cost 
per woman for the January to February 2009 cohort before fFN 
implementation and for the January to February 2010 cohort after fFN 
implementation.  
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Results: 
 
Before the introduction of the fFN test, there were 69 preterm antenatal 
admissions (22 – 34+6 weeks of gestation) over two months (January – 
February 2009). The majority of admissions were of singleton gestation 
(n=60), with some twins (n=7) and one triplet pregnancy. The most common 
reason for admission was for threatened preterm labour, (18/69, 26.1%, Table 
1). There were 7 women who had an in-utero transfer into UCLH, of whom 2 
had threatened preterm labour; 5 of the transfers were from within the 
NCLPN.  There were 2 women who had an in- utero transfer out of UCLH, 1 
for threatened preterm labour who subsequently delivered at term. Delivery 
outcomes of women admitted with threatened preterm labour are shown in 
Table 2. Of 18 women admitted with threatened preterm labour, only 16.7% 
(n=3) delivered during their admission (median 8 days from admission to 
delivery, range 3-13 days, total 24 bed days). Tocolysis (Atosiban) was 
administered to 27.7% (n=5). Over three-quarters of the women admitted with 
threatened preterm labour did not deliver in that admission (15/18, 83.3%). 
The median time from admission to discharge for these women who did not 
deliver was 2 days (range 1 to 48 days, total 132 bed days). The average cost 
of admission per woman during this two month period was £1,032 (95% CI 
£880 to £1184, Table 3). 
As part of implementation, the use and performance of the fFN test in 
our unit was evaluated ten weeks after its introduction. Over this time, 94 tests 
were carried out in 76 women with performance characteristics as shown: 
NPV 100% and PPV 43.8% for delivery within 2 weeks of the test, sensitivity 
100%, specificity 89.4%. Results of the audit were disseminated to all clinical 
staff and midwives. 
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Ten months after the introduction of the fFN test we conducted a re-
audit of all antenatal preterm admissions over a 2 month period (January and 
February 2010). There were 79 preterm admissions (22 – 35 weeks of 
gestation, Table 1). The majority of admissions were of singleton gestation 
(n=65), with some twins (n=14). The most common reasons for admission 
were for maternal medical problems, followed by preterm prelabour rupture of 
membranes. There were two women admitted for an incidental finding of a 
short CL<25mm at their anomaly scan. Only 11 women (13.9%) were 
admitted for threatened preterm labour, and 4 (36.3%) delivered during their 
admission (Table 2). The median time from admission to delivery was 3 days 
(range 1-18 days, total 29 bed days). The median time from admission to 
discharge for those who did not deliver was 3 days (range 1-8 days, total 25 
bed days). Only 1 woman admitted received tocolysis; she did not deliver 
during her admission and 7 women received steroids; none delivered during 
their admission. Of the women admitted with threatened preterm labour, 6 had 
a fFN test, of which 4 were positive. fFN was not performed in 5 women in 
threatened preterm labour due to contraindications to the test (cervical 
dilatation more than 3 cm, recent sexual intercourse and moderate or heavy 
vaginal bleeding). The average cost of admission per woman was £333 (95% 
CI £255 to £411, Table 3). 
The use and performance of the fFN test was evaluated during the re-
audit period (January to February 2010) to reassess test performance. In 41 
fFN tests conducted the characteristics were as follows: NPV 97% and PPV 
33% for delivery within 2 weeks of the test, sensitivity 100%, specificity 90%. 
For the year following fFN implementation the NPV for spontaneous preterm 
birth within 2 weeks of the test was 99.2%% (March 2009 to March 2010). 
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Comparing the mean cost per woman before (£1,032, 95% CI £880 to 
£1184) and after the introduction of fFN £333, 95% CI £255 to £411) resulted 
in a cost saving of £699 (95% CI £469 to £929) per woman (Table 3).  
 
Discussion: 
Our primary finding was that after introduction of fFN in a UK perinatal 
network level 3 hospital there was a sustained long-term reduction of in-
patient admissions, costs of transfer and administration of steroids and 
tocolysis. The negative predictive value of the test was high even at one year 
after introduction, with an approximate 30% false positive result. The negative 
predictive value had the most effect in our unit, in allowing us to confidently 
discharge those women who were least likely to need intervention and 
delivery prematurely. For women who did deliver preterm during their 
admission, the admission to delivery interval fell from a median of 8 days to 3 
days after introduction of the test, showing that as expected, implementation 
of the test selected women for admission who were most likely to deliver 
imminently. Prior to the introduction of the test the mean cost per woman was 
£1,032. Eighteen women were seen during the two month period. Over 12 
months this translates into 108 women, with a total cost of £111,456. 
Following the introduction of the fFN test the saving was £693 (95% CI £464 
to £922) per woman. If the annual number of 108 received the fFN test and 
were managed accordingly the total saving could be £74,844 (95% CI 
£50,112 to £99,576). Our economic analysis also demonstrates the significant 
cost saving that resulted even ten months after introduction of the test. The 
main cause of the saving was the decrease in the number of inpatient days 
followed by a lower use of tocolysis for women who were destined not to 
deliver. This is consistent with a systematic review with cost analysis of fetal 
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fibronectin based on modelled costs and unpublished data, which showed that 
admission rates had the largest effect on cost savings after introducing fetal 
fibronectin testing (Deshpande et al 2013). The reduction in tocolysis costs 
were less substantial and cost savings would be even lower in a unit that uses 
alternative unlicensed tocolytics.   
The strength of this study is that it was a prospective, planned 
implementation incorporating fFN testing into a threatened preterm labour 
algorithm using real life costs. We audited all antenatal admissions before 
implementation to determine how much the diagnosis of threatened preterm 
labour contributed to our total admissions. The study was supported by 
inclusive training for both midwives and doctors and was communicated 
around the perinatal network. There were no adverse outcomes. The 
weaknesses of our study are that it was confined to one centre within the 
perinatal network and we reaudited over a relatively short duration. A longer 
time period will be required to monitor the effect of fFN testing on the whole 
network, as any new policy takes time to be implemented to full effect 
(Musaad et al., 2005). Future audits are planned across our perinatal network 
to study the effect of fFN testing on transfers within the network, steroid and 
tocolytic use. 
 
Conclusions 
One year after its introduction, use of the fFN test in a tertiary level maternity 
unit lead to a sustained reduction in the hospital costs associated with women 
presenting in threatened preterm labour. The test carries an initial cost when 
applied to this patient group. The cost-savings are substantial and are mainly 
associated with a reduction in inpatient stay.  
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Table 1: Primary reasons for preterm antenatal admission at 22 to 34+6 
weeks of gestation 
 
Primary diagnosis Jan – Feb 
2009 
% Jan – Feb 
2010 
% 
Threatened preterm labour 18 26.1 11 13.9 
Established preterm labour 2 2.9 3 3.8 
PPROM 4 5.8 13 16.4 
Maternal medical indication*  11 15.9 17 21.5 
APH other than placenta praevia 8 11.6 8 10.1 
Placenta praevia 5 7.2 2 2.5 
Gestational hypertension 7 10.1 9 11.4 
Fetal medicine indication∆ 6 8.7 9 11.4 
Fibroid-related pain 3 4.3 1 1.2 
Incidental short cervix (<25mm)** 0 0 2 2.5 
Not answered 5 7.2 0 0 
Total number of admissions  69 100% 79 100% 
*Maternal medical indications included management of diabetes, suspected pulmonary 
embolus, infections, systemic lupus erythematosus and headache 
∆Fetal medicine indications included fetal growth restriction, and fetal structural abnormalities 
APH: antepartum haemorrhage 
Gestational hypertension includes PET: pre-eclampsia and PIH: pregnancy induced 
hypertension 
PPROM: Preterm premature rupture of the membranes 
**Note: Routine screening for cervical length at the 20 week anomaly scan was introduced 
between the two audit periods 
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Table 2: Antenatal preterm admissions (22 – 34+6 weeks of gestation) 
for threatened preterm labour and their management before and after 
introduction of the fFN test.  
 
Cases Jan-Feb 2009  Jan-Feb 2010  
Total number of preterm 
admissions 
69 79 
Threatened preterm labour 
admissions 
18  11 
In utero transfers in or out for 
threatened preterm labour 
3 2 
Cases of threatened preterm labour in which women did deliver 
Preterm births  3 4 
Admission to delivery  
total number of bed days, 
(median length of stay) 
24 days total,  
(8 days) 
29 days total, 
(3 days) 
Cases of threatened preterm labour in which women did not 
deliver 
Number of admissions 14 7 
Admission to discharge  
total number of bed days, 
(median length of stay)  
132 days total, 
(2 days)  
25 days total, 
(3 days) 
Maternal steroid treatment  11/14   7/7 
Tocolysis treatment  5/14   1/7 
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Table 3: Total resource use and cost of patients presenting with threatened preterm labour before and after 
implementation of the fFN test. 
 
 
Cost components and unit 
costs 
Jan-Feb 2009 cohort before fFN implementation (N=69) Jan-Feb 2010 cohort after fFN implementation (N=79) 
Resource use data  
Cost per patient, 
mean £ (95% CI) 
Resource use data  
Cost per patient, 
mean £ (95% CI) Cost components 
Unit 
costs, £ 
Full, count 
Minor, 
count 
Combined, count 
(mean, std. err.) 
Full, count 
Minor, 
count 
fFN only 
Combined, count 
(mean, std err.) 
Inpatient days* 420 72 days 84 days 156 days (2.26, 0.18) 950 (801 - 1099) 8 days 46 days 0 days 54 days (0.68, 0.09) 287 (211 - 364) 
FBC 12 8 tests 10 tests 18 tests (0.26, 0.06) 3 (2 - 5) 1 test 10 tests 2 tests 13 tests (0.16, 0.04) 2 (1 - 3) 
Group and Save 20 8 tests 10 tests 18 tests (0.26, 0.06) 5 (3 - 8) 1 test 10 tests 0 tests 11 tests (0.14, 0.04) 3 (1 - 4) 
MSU 20 8 tests 10 tests 18 tests (0.26, 0.06) 5 (3 - 8) 1 test 10 tests 10 tests 21 tests (0.27, 0.06) 5 (3 - 8) 
HVS 25 8 tests 10 tests 18 tests (0.26, 0.06) 7 (4 - 10) 1 test 10 tests 8 tests 19 tests (0.24, 0.06) 6 (3 - 9) 
Ultrasound scan 70 6 scans 10 scans 16 scans (0.23, 0.06) 16 (8 - 24) 1 scan 9 scans 0 scans 10 scans (0.13, 0.04) 9 (3 - 14) 
Atosiban 339 8 Rx 0 Rx 8 Rx (0.12, 0.04) 39 (12 - 67) 1 Rx 0 Rx 0 Rx 1 Rx (0.01, 0.01) 4 (-4 - 13) 
Atosiban infusion 
equipment¶ 
5 8 Rx 0 Rx 8 Rx (0.12, 0.04) 1 (0 - 1) 1 Rx 0 Rx 0 Rx 1 Rx (0.01, 0.01) 0 (0 - 0) 
Maternal steroid 
injection 
5 8 Rx 6 Rx 14 Rx (0.20, 0.05) 1 (0 - 2) 1 Rx 10 Rx 0 Rx 11 Rx (0.14, 0.04) 1 (0 - 1) 
In utero transfer 100 2 transfers 0 transfers 2 transfers (0.03, 0.02) 3 (-1 - 7) 0 transfers 1 transfers 0 transfers 1 transfer (0.01, 0.01) 1 (-1 - 4) 
Analgesia 10 8 Rx 10 Rx 18 Rx (0.26, 0.06) 3 (1 - 4) 1 Rx 10 Rx 5 Rx 16 Rx (0.20, 0.05) 2 (1 - 3) 
fFN test 35 0 tests 0 tests 0 tests (0.00, 0.00) 0 (0 - 0) 1 test 10 tests 31 tests 42 tests (0.53, 0.08) 19 (13 - 24) 
Mean cost per woman, £                                                                                        1032 (880 - 1184)                                                                                                              339 (261 - 417) 
 
fFN = fetal fibronectin; FBC = full blood count; MSU = mid stream urine culture; HVS =high vaginal swab for culture; Full: full admission defined as hospital 
admission, laboratory investigations, a fetal ultrasound scan if clinically indicated, use of analgesia, steroids, tocolysis and in utero transfer if necessary; 
Minor: minor admission defined as hospital admission, laboratory investigations, a fetal ultrasound scan, use of analgesia, steroids and in utero transfer if 
necessary; Rx: prescription. 
* Total inpatient days in full or minor admission group until discharge or delivery if delivered during admission 
¶ Includes syringe pump, syringe and giving set 
 
